FDA
-
-
-
-
-
-
-
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
-
-
-
-
-
-
-
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
-
-
-
-
-
-
-
Theratechnologies (THTX) Announces FDA Approval of Trogarzo
-
-
-
-
-
-
-
Theratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration Study
-
-
-
-
-
-
-
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
-
-
-
-
-
-
-
Theratechnologies' (THTX) Trogarzo Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
-
-
-
-
-
-
-
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
-
251,254 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All